Ozempic and similar weight loss drugs may lower risk of 42 health conditions
The American Food and Drug Administration's approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide-1 agonists, or GLP-1.
Ziyad Al-Aly - Today, GLP-1 drugs, including Wegovy, Mounjaro and Zepbound, have become household names and key tools in the fight against obesity: 1 in 8 American adults say they
...
As jy n aktiewe intekenaar is en die artikel wys nie, meld asseblief af en weer aan. Gratis toegang tot artikels vanaf 12:00.
Kommentaar
Republikein
Geen kommentaar is op hierdie artikel gelaat nie